Julian Symons
Vermögen: 148 524 $ am 31.07.2026
Vermögen: 148 524 $ am 31.07.2026
Julian A. Symons is Chief Scientific Officer & Executive VP at Aligos Therapeutics, Inc. since 2018.
Formerly, Dr. Symons was Vice President-Disease Area Research & Development at Alios BioPharma, Inc. from 2015 to 2018.
Education includes a doctorate from York University and an undergraduate degree from the University of Central Lancashire.
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 31.03.2026 | 35’112 ( 0.65% ) | 148 524 $ | 31.07.2026 |
| Unternehmen | Position | Beginn |
|---|---|---|
| ALIGOS THERAPEUTICS, INC. | Technik-/Wissenschafts-/F&E-Leiter | 01.05.2018 |
| Unternehmen | Position | Ende |
|---|---|---|
Alios BioPharma, Inc.
Alios BioPharma, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical stage biopharmaceutical company which develops novel antiviral therapies for the treatment of respiratory diseases | Corporate Officer/Principal | 01.04.2018 |
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
| Private Unternehmen | 4 |
|---|---|
Alios BioPharma, Inc.
Alios BioPharma, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical stage biopharmaceutical company which develops novel antiviral therapies for the treatment of respiratory diseases | Health Technology |
York University
York University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of Central Lancashire
University of Central Lancashire Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Aligos Therapeutics, Inc.
Aligos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops targeted, curative therapies for hepatologic diseases and viral infections | Health Technology |
Bitte wählen Sie Ihre Ausgabe
Alle länderspezifischen Finanzinformationen